Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

NCT02794883 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Malignant Glioma
Recurrent Glioblastoma

Interventions

BIOLOGICAL: Durvalumab
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Surgical Procedure
BIOLOGICAL: Tremelimumab

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]